GlassScriptPhysician profile
Thomas A Alfreda
NPI 1487824041
$7,056.78
in general payments reported to CMS, 2019-2025
52 companies · $690 in 2025
The $690 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,125 · 2020: $584 · 2021: $762 · 2022: $970 · 2023: $1,500 · 2024: $1,425 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,615.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,341.83 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $459.28 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $394.97 | 2019-2022 | |
| Lilly USA, LLC | $368.35 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Allergan, INC. | $349.56 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $336.50 | 2022-2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $288.42 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $222.18 | 2019-2025 | |
| Abbott Laboratories | $202.61 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $169.46 | 2022-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $168.08 | 2019-2021 | |
| Baxter Healthcare | $166.09 | 2023 | Hillrom - Life 2000 Ventilation System |
| Endo Pharmaceuticals INC. | $165.91 | 2019-2024 | Aveed |
| Bayer Healthcare Pharmaceuticals INC. | $157.38 | 2022-2023 | |
| Novo Nordisk INC | $154.52 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Alfreda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.